openPR Logo
Press release

Mucopolysaccharidosis Treatment Market Details 2017 - 2027: Future Demands, Dynamics, Upcoming Trend, Business Opportunities, Growth by BioMarin Pharmaceutical, Inc., Genzyme, a Sanofi Company, ArmaGen

02-15-2019 01:49 PM CET | Health & Medicine

Press release from: Future Market Insights

Mucopolysaccharidosis Treatment Market Details 2017 - 2027:

The mucopolysaccharidosis (MPS) is an inherited lysosomal storage disorders. It refers to the deficiency of the enzyme that is involved in the degradation of acid mucopolysaccharides. The enzyme is known as glycosaminoglycans (GAGs). Mucopolysaccharidosis affects many parts of the body and is caused due to the mutation of the IDUA gene. Due to the mutation of the IDUA gene, larger sugar molecules known as glycosaminoglycans, accumulate in the cells known as lysosomes. This results in the increase in the size of the lysosomes, causing enlargement of the different tissues and organs of the body. The mucopolysaccharidosis (MPS) is classified as Hurler syndrome (MPS IH), Hurler-Scheie syndrome (MPS I-H/S), Sanfilippo syndrome (MPS III), Scheie syndrome (MPS IS), Hunter syndrome (MPS II), Maroteaux-Lamy syndrome (MPS VI), Morquio syndrome (MP IV), and Sly syndrome (MPS VII). Though there is no cure to Mucopolysaccharidosis I (MPS I), the treatment option includes bone marrow transplant, enzyme replacement therapy, that helps to manage the symptoms to some extent.

The symptoms of the mucopolysaccharidosis I (MPS I) are not present at the time of birth, but apprers during childhood. The most common signs and symptoms includes, Enlarged vocal cords, resulting in a deep voice with enlarged head, lips, tongue and nose, sleep apnea, upper respiratory infection, hearing loss, Carpal tunnel syndrome, joint deformities and others. The symptoms vary from person to person. The management of mucopolysaccharidosis I (MPS I) includes primary care with pulmonology, gastroenterology, cardiology, dental, physical therapy specialist .The Aldurazyme is a drug used as an enzyme replacement therapy for MPS I

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Advancement in the treatment options includes intense research and development with government funding. The Orphan Disease Center is offering MPS I Pilot Grant Programs for improving the therapies for people suffering from this syndrome. The Lysosomal Disease Network includes doctors, nurses, researchers and others who are working to improve the lives of people suffering from this disorder. Increasing focus of major biopharmaceutical companies on research and development of drugs for treatment of rare diseases is expected to boost demand for mucopolysaccharidosis treatment drugs. Moreover, the number of treatment options currently in pipeline is expected to increase revenue growth during the forecast period.

Mucopolysaccharidosis treatment Market: Drivers and Restrains

Rise in number of people suffering from Lysosomal diseases, financial incentives for orphan drug development to recover R&D costs, including market exclusivity, tax waiver, fee reductions and, grants, success for the drugs in pipeline with faster market access, high burden of rare diseases, favorable regulations for orphan products development are some of the factors favoring market growth over the forecast period. The factors limiting the market growth is high treatment cost, heterogeneity of the disease, lack of treatment options, lack of awareness and others are some of the factors restraining the growth of the market . growth opportunities such as increase in R&D for orphan drugs driven by consolidation of Pharma-biotech firms in mucopolysaccharidosis treatment, initiatives to improve diagnosis, research and development in therapies targeting neuropathic lysosomal storage disorder by crossing blood brain barrier (BBB) is boosting the growth of the target market

Mucopolysaccharidosis treatment Market: Segmentation

The global Mucopolysaccharidosis treatment market has been classified on the basis of treatment type, end user and geography.

Based on Product Type, the global Mucopolysaccharidosis treatment market is divided into following:

Enzyme Replacement Therapy
Stem Cell Therapy
Others

Based on the End User, the global Mucopolysaccharidosis treatment market is divided into following:

Hospitals
Clinics
Specialty Care Unit
Others

Mucopolysaccharidosis treatment Market: Overview

The Mucopolysaccharidosis treatment market is segment based on treatment type, end-user and geography. Based on the product type, Mucopolysaccharidosis treatment market is segmented on the basis of enzyme replacement therapy, stem cell therapy and others. Reimbursement varies from state to state for Medicaid program and there are some restrictions for Medicaid coverage for rare disease drugs. For instance, In state of Georgis, clinically superior cystinosis agent is not reimbursed. In 2016, State of Oregon expanded the class of covered therapies to include drugs for Gaucher's disease, MPS I, MPS II, MPSIV and MPS VI. On the basis on end user, the Mucopolysaccharidosis treatment market is segmented on the basis of hospital, clinics, and specialty care units. Increase in the number of patient population, focus of large pharmaceutical companies in research and development will increased the demand for Mucopolysaccharidosis treatment market.

Mucopolysaccharidosis treatment Market: Regional Overview

Region wise, the global Mucopolysaccharidosis treatments market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is estimated to account for major share due to favorable regulations for orphan products development, funding for research and development. Over the last few years, introduction of specific orphan drug regulations has enabled and accelerated research and development of therapies for treatment of several rare diseases. Health plan coverage and reimbursement policies for such costly drugs also influence the investment by pharmaceutical and biotechnology companies to invest in drug development of such costly drugs. Significant economic development has led to an increase in healthcare availability in Asia Pacific region providing an opportunity for biopharmaceutical companies to penetrate in Asia Pacific regions, rising awareness towards lysosomal storage diseases, collaborations to develop new class of medicine for lysosomal storage diseases are some of the factors fueling growth of the market

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-5880

Mucopolysaccharidosis treatment Market: Key Players

Some of the key players in global mucopolysaccharidosis treatment market are BioMarin Pharmaceutical, Inc., Genzyme, a Sanofi Company, ArmaGen, Inc., Sangamo Therapeutics and others

ABOUT US:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mucopolysaccharidosis Treatment Market Details 2017 - 2027: Future Demands, Dynamics, Upcoming Trend, Business Opportunities, Growth by BioMarin Pharmaceutical, Inc., Genzyme, a Sanofi Company, ArmaGen here

News-ID: 1592443 • Views: 305

More Releases from Future Market Insights

How Changing Dynamics of Cable Testing Market are Reflecting on Growth Strategie …
Global Cable Testing Market: Introduction The cost of the substitution of cables that are concealed is very high. Faults in the cable, bending, kinking, and crushing, are not always visible, which has created the requirement for cable testing. Thus, cable testing helps check the cable functionality, cable quality, and cable conformity. Several times, cable testing by visual inspection is an effective way of identifying the actual problem before it causes any
How Transformative Trends in Self-Organising Network Market are Molding Strategi …
Self-Organising Network: Introduction With accelerated advancements and increasing complexities in the radio network technologies, such as those utilised for the development of LTE and 5G networks, which are used for planning, management, configuration, healing and optimisation, are required to be automated to facilitate efficiency. At present, suppliers are offering self-organising networks that possess the ability to offer optimum performance. Self-organising networks are use cases that perform network governance, including network planning,
Mining Vehicle AC Kits Market: Exploring the Impact of Trends on Strategies of K …
Mining Vehicle AC Kits Market: Introduction Cabin space in mining equipment has become more sophisticated in the recent past. The installation of mining vehicle AC kits has evolved from an optional feature to a necessary feature. Mining equipment manufacturers have made advancements in technology related to efficiency, performance and cost of air conditioning systems in order to make them affordable and economical to enable low-budget and compact installations without compromising on
Key Factors to Fuel Growth of the Talent Acquisition & Staffing Technology and S …
With the growing importance of recruiting and retaining top talent effectively and efficiently, smart hiring processes are the need of the hour. It is about time organisations move beyond merely scrutinising resumes. Salaries and benefits are important factors, but adopting ways that would make candidates an important part of the hiring process will attract the best talent. Studies reveal that due to discrepancies in existing Applicant Tracking Systems (ATS), hiring

All 5 Releases


More Releases for MPS

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems. Download the sample report @ https://www.pharmaproff.com/request-sample/1146 In later stages of this disorder, people
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics - Pipeline Analys …
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. Earlier, MPS I disorder was divided into three separate syndromes; Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Download the sample report at: https://www.pharmaproff.com/request-sample/1144 Later on, these were clubbed as one disease, due to overlap between each of these three syndromes. Children with MPS I
Electromagnetic Therapy Device Market Study Report 2019| Orthofix Holdings, BEME …
The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Electromagnetic Therapy Device market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Electromagnetic Therapy Device market. The authors of the report have segmented the global Electromagnetic Therapy Device Market as per
Global Electromagnetic Therapy Device Market 2019 - Orthofix Holdings, BEMER, Do …
The global "Electromagnetic Therapy Device Market" report delivers a comprehensive and systematic framework of the Electromagnetic Therapy Device market at a global level that includes all the key aspects related to it. The data is collected from different sources allied to the global Electromagnetic Therapy Device market and the research team meticulously analyze the gathered data with the help of various analytical tools and present their opinion based on analysis
Managed Print Services (MPS) Industry Is Moving Fast | Opportunities & Challenge …
The Report provides a basic overview of the Managed Print Services (MPS) Market including definitions, classifications, applications and chain structure. The Managed Print Services (MPS) Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regional development status. The detailed report of Global Managed Print Services (MPS) Market evaluated by skilled experts is segmented into Application and Product. The Global Managed Print Services (MPS) Market
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom. Led by